60 results about "Mannose binding" patented technology

The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species, especially human patients, with variants of the E. coli FimCH protein that elicit antibodies that have better functional inhibitory activity than antibodies raised against wild type protein. In particular, such variants include mutations that promote a more open confirmation of the FimH protein, particularly in regions involved in mannose binding, to expose regions previously poorly exposed and mutations that abolish a significantly reduce mannose binding. In another aspect, the invention provides antibodies against such proteins and protein complexes that may be used in passive immunization to protect or treat pathogenic bacterial infections. The present invention also provides machine readable media embedded with the three-dimensional atomic structure coordinates of FimCH bound to mannose, and subsets thereof, and methods of using the crystal structure to provide candidate amino acid residues for mutation.

The present inventors have shown that MASP-depleted MBL is able to recruit MASPs from plasma and successfully activate complement cascade. Furthermore, it has been discovered that MBL purified as a complex has limited ability to activate the complement cascade when compared to MASP-depleted MBL. Accordingly, the present invention provides a pharmaceutical composition comprising an isolated non-recombinant mannose binding lectin (MBL) substantially free from activated MBL associated serine proteases (MASPs) together with a pharmaceutically acceptable carrier or diluent. Also provided is a method of treating a subject in need of MBL comprising administering to the subject an effective amount of a pharmaceutical composition of the invention.

Fusion proteins having sequences that target specific moieties such as carbohydrates, lipids, and/or proteins that are associated with certain cell types and/or pathogens; and a sequence that induces effector function are provided. The disclosure also provides nucleic acids encoding the fusion proteins, as well as pharmaceutical compositions, methods of use, and methods of treating conditions or diseases such as infectious diseases, cancers, immune related disorders and other ailments, that include the fusions proteins described herein.

The present disclosure is directed to methods and compositions for treating osteoarthritis and preventing osteoarthritis, by administering a compound that modulates one or more components in the complement system. In one embodiment, a compound that inhibits a component in the complement system is administered to prevent, delay the progression of, or treat osteoarthritis. In other embodiments, compounds with specific inhibition of a component in a particular pathway in the complement system, such as the alternative, mannose binding lectin, and/or classical pathway, are administered to a subject having osteoarthritis or at risk of developing osteoarthritis.

The present invention relates to pharmaceutical compositions comprising MBL and/or MBL variants. In particular the invention relates to pharmaceutical compositions comprising at least 200 mug/ml protein containing material, wherein mannan binding lectin (MBL) and/or MBL variants constitutes at least 35% (w/w) of the total protein; or to compositions comprising at least 400 mug/ml mannan binding lectin (MBL) and/or MBL variants. In addition the invention relates to pharmaceutical compositions comprising MBL and/or MBL variants and divalent cations. The invention also describes methods of preparing said compositions. The pharmaceutical compositions according to the invention may for example be used in methods of treatment of a number of different clinical conditions including infections. Uses of the compositions for preparation of medicaments for treatment of a clinical condition are also described.

This application relates to methods of predicting susceptibility or likelihood of a clinically-relevant mannose-binding lectin (MBL)-deficient subject to develop a cardiovascular disease and/or cardiodiabetes. The methods include measuring MBL mass or concentration and, optionally, measuring MBL activity, at least one other biomarker and/or genotyping of MBL gene and its promoters; combining the information obtained into a calculated MBL-inclusive index score that involves mathematical transformation; and assigning a risk of cardiadiabetic status and clinical endpoints based on the determination and comparison of the MBL inclusive index to reference values from a population.

The present invention provides a vaccine composition comprising a collectin such as mannose binding protein (MBL) and an immunogenic determinant. The invention also describes methods of immunizing individuals with the compositions, and the use of collectins in the preparation of vaccine compositions.

The invention relates to a gene for improving the cadmium accumulation and the tolerance of a plant, and application thereof. The gene for improving the cadmium accumulation and the tolerance of the plant has a sequence as shown in a sequence table SEQ ID No:1, and is applied to repairing cadmium-polluted soil. The gene for improving the cadmium tolerance of the plant is transferred into the plantso as to be overexpressed in the plant, and the plant is cadmium-tolerant. A research result shows that under the condition of cadmium treatment, through overexpressing an MYB4 gene, the gene can bebinded with mannose, and the increased expression of related genes such as GSH1, GSH2, PCS1 and PCS2 is promoted, so that the contents of GSH and PC are increased; an external cadmium ion is stored invacuole, and the cadmium tolerance is expressed.

A nucleotide (cDNA) sequence of Alocasia agglutinin protein, its coding amino acid (AA) polypeptide sequence, the process for using the gene to transform cotton or other plants, and its application in medicine or other fields are disclosed. Said gene is a member of mannose conjugated agglutinin gene family and is a constitutively expressed gene.

The invention relates to an immunochromatography kit for fluorescently and quantitatively detecting MBL (mannose-binding lectin). The immunochromatography kit comprises a fluorescence test strip and sample diluent, wherein the fluorescence test strip comprises a bottom plate, a sample pad, a fluorescence binding pad, an enveloped membrane and absorbent paper are sequentially bonded on the upper surface of the bottom plate from one end to the other end, the inner end of the sample pad is lap-jointed with one end of the fluorescence binding pad, the other end of the fluorescence binding pad is lap-jointed with one end of the enveloped membrane, and the other end of the enveloped membrane is lap-jointed with the absorbent paper, wherein the enveloped membrane comprises a detection zone and a quality control zone, the detection zone is enveloped with anti-MBL monoclonal antibody, and the quality control zone is enveloped with goat anti-rabbit IgG; and the fluorescence binding pad contains fluorescently-labeled MBL monoclonal antibody and fluorescently-labeled goat anti-rabbit IgG. The immunochromatography kit for fluorescently and quantitatively detecting MBL has strong specificity and high sensitivity, the detection result acquisition time is short, the operating mode is convenient and simple, and the detection result is accurate and reliable.

The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.

An application of the polygonalectin II protein is preparing the medicine for preventing and reating hepatitis B and AIDS is disclosed as it can effectively suppress the HepG2.2.1.5 cell to secret antigens HBeAg and HBsAg, and the activity of HIV.

Disclosed is Polygonatum cyrtonema Hua.Lectin II (PCL II), a plant protein isolated and purified from Siberian solomonseal rhizome, which has very strong inhibitory action to human immunodeficiency virus (HIV), thus can be used for preparing medicament for the prevention and treatment of AIDS.

The invention relates to a method for early diagnosing an acute kidney injury caused by a contrast medium by utilizing urine MBL (mannan-binding lectin), which comprises the following steps of: comparing fluorescence difference electrophoresis charts of the urine of a patient 24 hours after an operation and the basis urine of the patient before the operation, and searching out a plurality of differentially expressed protein spots; identifying through a matrix-supported laser desorption ionization time of flight mass spectrometry technique to discover that the mannan-binding lectin (MBL) and serine protease related to the MBL are both increased in the differentially expressed protein spots, and the difference has a statistical significance for prompting that the acute kidney injury caused by the contrast medium is related to a pathway of MBL (mannan-binding lectin) complement activation, which is verified by a patient with the kidney injury caused by the contrast medium through an urine ELISA (enzyme-linked immuno sorbent assay) way. If applied to the clinic, the method of the invention can be used for detecting the urine MBL (mannan-binding lectin) 24 hours after an operation through the ELISA (enzyme-linked immuno sorbent assay) way and early diagnosing the kidney injury caused by the contrast medium, which is 24 hours earlier than the diagnosis of serum creatinine, and provides basis for early clinical diagnosis, early treatment and improvement of prognosis.

The present invention relates to methods and compositions for regulating lectin complement pathway (LCP)-associated complement activation. In particular, the invention relates to methods and compositions for inhibiting LCP-associated complement activation in order to inhibit hyperglycemic myocardial damage. The invention also relates to the treatment of cardiomyopathy and/or hypertrophy, such as cardiac hypertrophy. The invention also relates to methods and compositions for inhibiting the loss of cardiac progenitor cells by inhibiting LCP-associated complement activation. The methods include both in vitro and in vivo methods. The methods can be accomplished by contacting a mammalian cell having a surface exposed mannose binding lectin (MBL) ligand, such as a cardiac cell, with an effective amount of a MBL inhibitor to inhibit LCP-associated complement activation.

The present invention relates to the PCR product sequencing assay of mannose-binding lectin gene (MBL) correlative with the susceptibility of SARS-CoV infection. The present invention also relates to the assay of the haplotypes correlative with the susceptibility of SARS-CoV infection that is composed of three single nucleotide polymorphism sites(SNPs): MBL gene G-550C,G-221C and G+230A. The said assay is to determine the genotype of the three SNPs by sequencing the PCR product first and then to calculate the haplotypes with PHASE programme. The present invention further relates to the detection kit of the above SNPs and the usage. Furthermore, the present invention combines the G+230A polymorphism sites and the haplotype composed of G-550C,G-221C and G+230 with SARS-CoV susceptibility, confirms that MBL is a new susceptibility gene included in SARS-CoV infection, and provides new genetic counseling content for the prevention and control of SARS-CoV infection of the population.

The invention relates to a rapid detection method of TTK enzyme activity and an application of the rapid detection method. The detection method includes 1), taking a to-be-detected sample, blank control and positive control to perform co-incubation with TTK enzyme and MBP/ATP (mannose-binding protein/adenosine triphosphate) mixture respectively to produce ADP (adenosine diphosphate); 2), respectively adding ADP-Glo<TM> reaction reagents to three groups of kinase reaction systems for co-incubation, and terminating the kinase reaction and consuming the remaining TAP; 3), respectively adding kinase detection reagents to the reaction systems for co-incubation to convert ADP to ATP, and reading the luminous value RLU of the newly synthesized ATP; 4), calculating the TTK enzyme activity according to the formula: the enzyme activity=(RLU(Sample)-RLU(Blank))/(RLU(Pos.Ctrl)-RLU(Blank))X100%. On the basis of ADP-Glo<TM> kinase experiment, the reaction process is quantified by direct direction ofATP consumed in the reaction; the reaction is carried out in 384-hole plates, which does not involve repeated suction and washing process, the operation error is small, the flux is increased, and themethod is suitable for a large number of microhole plate operation combined with high-flux liquid transfer workstation equipment; the method is stable in system, high in precision and can be used forscreening TTK target inhibitors and TTK target related drugs.

The invention provides a synthesis method of a nanoparticle surface modifier. A chemical synthesis method is utilized to combine water-soluble dithiodiols with mannitose to obtain dithiodiol mannitose derivatives. The products can be used for carrying out functionalization modification on Au, Ag, Cd and other metals and semiconductor material surfaces under the covalent combination action of the sulfhydryl group, and the bare mannitose structure on the other end can be specifically combined with canavaline (ConA). The mannitose derivative modified/silver nanoparticle process and the specific recognition process of ConA and mannitose can be characterized by obvious changes (generally red shift) of the SPR image color of the mono nanoparticles in real time under a dark field microscope (DFM). The saccharide-nanoparticles obtained by surface modification of the functional molecule are low in toxicity and stable in the solution, and have the advantages of favorable biocompatibility, favorable stability and efficient targeted recognition capability for trace canavaline.